Asthma Marijuana Treatment References

Pollen Allergy / Hay Fever

 

 

 

 

 

Asthma Marijuana Treatment References

REFERENCES

1. Zias J., Stark H., Sellgman J., et al. Early medical use of cannabis. Nature. 1993;363:215. [PubMed]
2. Schlesinger S. Untersuchung der Cannabis sativa. Repertorium fur die Pharmacie. 1840:190–208.
3. Decourtive E. Note sur le haschisch. CR Hebd Séances Acad Sci. 1848;26:509–510.
4. Mechoulam R. Cannabinoid chemistry. In: Mechoulam R, ed. Marijuana. New York, NY; London, UK: Academic Press. 1973:1–99.
5. Mechoulam R., Hanus L. A historical overview of chemical research on cannabinoids. Chem Phys Lipids. 2000;108:1–13. [PubMed]
6. Gaoni Y., Mechoulam R. Isolation, structure and partial synthesis of the active constituent of hashish. J Am Chem Soc. 1964;86:1646–1647.
7. Waller CW. JJ., Buelke J., Turner CE. Marihuana, an annotated bibliography. Res Inst Pharmacy Sci Univ Mississippi. 1976 and yearly updates.
8. Fraser JD. Withdrawal symptoms in cannabis indica addicts. Lancet. 1949;2:747. [PubMed]
9. Grinspoon L., Bakalar JB., Zimmer L., Morgan JP. Marijuana addiction. Science. 1997;277:749–author reply 750-742. [PubMed]
10. Kaymakcalan S. The addictive potential of cannabis. Bull Narc. 1981;33:21–31. [PubMed]
11. Jones RT., Benowitz N., Bachman J. Clinical studies of cannabis tolerance and dependence. Ann N Y Acad Sci. 1976;282:221–239. [PubMed]
12. Nordstrom BR., Levin FR. Treatment of cannabis use disorders: a review of the literature. Am J Addict.2007;16:331–342. [PubMed]
13. Bernoussi A., Brandibas G. Cannabis addiction and Telic Dominance Scale. Encephale. 2003;29:519–526. [PubMed]
14. Budney AJ., Moore BA., Rocha HL., Higgins ST. Clinical trial of abstinencebased vouchers and cognitive-behavioral therapy for cannabis dependence. J Consult Clin Psychol. 2006;74:307–316.[PubMed]
15. Gardner EL. Addictive potential of cannabinoids: the underlying neurobiology. Chem Phys Lipids.2002;121:267–290. [PubMed]
16. Maldonado R., Rodriguez de Fonseca F. Cannabinoid addiction: behavioral models and neural correlates. J Neurosci. 2002;22:3326–3331. [PubMed]
17. Mansbach RS., Nicholson KL., Martin BR., Balster RL. Failure of Delta(9)-tetrahydrocannabinol and CP 55,940 to maintain intravenous self-administration under a fixed-interval schedule in rhesus monkeys. Behav Pharmacol. 1994;5:219–225. [PubMed]
18. Colombo G., Serra S., Vacca G., Carai MA., Gessa GL. Endocannabinoid system and alcohol addiction: pharmacological studies. Pharmacol Biochem Behav. 2005;81:369–380. [PubMed]
19. Wang L., Liu J., Harvey-White J., Zimmer A., Kunos G. Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc Natl Acad Sci U S A. 2003;100:1393–1398. [PMC free article] [PubMed]
20. Cohen C., Perrault G., Voltz C., Steinberg R., Soubrie P. SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopaminereleasing effects of nicotine in rats. Behav Pharmacol. 2002;13:451–463. [PubMed]
21. Miller NS., Gold MS., Klahr AL. The diagnosis of alcohol and cannabis dependence (addiction) in cocaine dependence (addiction). Int J Addict. 1990;25:735–744. [PubMed]
22. Foltin RW., Fischman MW., Pippen PA., Kelly TH. Behavioral effects of cocaine alone and in combination with ethanol or marijuana in humans. Drug Alcohol Depend. 1993;32:93–106. [PubMed]
23. Lukas SE., Sholar M., Kouri E., Fukuzako H., Mendelson JH. Marihuana smoking increases plasma cocaine levels and subjective reports of euphoria in male volunteers. Pharmacol Biochem Behav.1994;48:715–721. [PubMed]
24. Ballon N., Leroy S., Roy C., et al. (AAT)n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean population. Pharmacogenomics J. 2006;6:126–130.[PubMed]
25. Filip M., Golda A., Zaniewska M., et al. Involvement of cannabinoid CB1 receptors in drug addiction: effects of rimonabant on behavioral responses induced by cocaine. Pharmacol Rep. 2006;58:806–819.[PubMed]
26. Le Foll B., Goldberg SR. Rimonabant, a CB1 antagonist, blocks nicotineconditioned place preferences. Neuroreport. 2004;15:2139–2143. [PubMed]
27. Cohen C., Perrault G., Griebel G., Soubrie P. Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology. 2005;30:145–155. [PubMed]
28. Castane A., Berrendero F., Maldonado R. The role of the cannabinoid system in nicotine addiction. Pharmacol Biochem Behav. 2005;81:381–386. [PubMed]
29. Einecke D. [A new pill for metabolic syndrome. Successful control of lipids, kilos and cigarettes]. MMW Fortschr Med. 2004;146:10–11. [PubMed]
30. Foulds J., Burke M., Steinberg M., Williams JM., Ziedonis DM. Advances in pharmacotherapy for tobacco dependence. Expert Opin Emerg Drugs. 2004;9:39–53. [PubMed]
31. Gelfand EV., Cannon CP. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert Opin Investig Drugs.2006;15:307–315. [PubMed]
32. Yao L., McFarland K., Fan P., Jiang Z., Ueda T., Diamond I. Adenosine A2a blockade prevents synergy between mu-opiate and cannabinoid CB1 receptors and eliminates heroin-seeking behavior in addicted rats. Proc Natl Acad Sci U S A. 2006;103:7877–7882. [PMC free article] [PubMed]
33. Ledent C., Valverde O., Cossu G., et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science. 1999;283:401–404. [PubMed]
34. Laviolette SR., Grace AA. The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction. Cell Mol Life Sci. 2006;63:1597–1613. [PubMed]
35. Le Foll B., Goldberg SR. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther. 2005;312:875–883. [PubMed]
36. Solowij N., Stephens RS., Roffman RA., et al. Cognitive functioning of longterm heavy cannabis users seeking treatment. JAMA. 2002;287:1123–1131. [PubMed]
37. Klugman A., Gruzelier J. Chronic cognitive impairment in users of ‘ecstasy’ and cannabis. World Psychiatry. 2003;2:184–190. [PMC free article] [PubMed]
38. Wadsworth EJ., Moss SC., Simpson SA., Smith AP. Cannabis use, cognitive performance and mood in a sample of workers. J Psychopharmacol. 2006;20:14–23. [PubMed]
39. Jager G., Kahn RS., Van Den Brink W., Van Ree JM., Ramsey NF. Long-term effects of frequent cannabis use on working memory and attention: an fMRI study. Psychopharmacology (Berl).2006;185:358–368. [PubMed]
40. Maj PF., Collu M., Fadda P., Cattaneo A., Racagni G., Riva MA. Long-term reduction of brain-derived neurotrophic factor levels and signaling impairment following prenatal treatment with the cannabinoid receptor 1 receptor agonist (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinyl-methyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone. Eur J Neurosci. 2007;25:3305–3311. [PubMed]
41. Huizink AC., Mulder EJ. Maternal smoking, drinking or cannabis use during pregnancy and neurobehavioral and cognitive functioning in human offspring. Neurosci Biobehav Rev. 2006;30:24–41.[PubMed]
42. Fried PA., Smith AM. A literature review of the consequences of prenatal marihuana exposure. An emerging theme of a deficiency in aspects of executive function. Neurotoxicol Teratol. 2001;23:1–11.[PubMed]
43. Murray RM., Morrison PD., Henquet C., Di Forti M. Cannabis, the mind and society: the hash realities. Nat Rev Neurosci. 2007;8:885–895. [PubMed]
44. Solowij N., Michie PT. Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia? J Psychiatry Neurosci. 2007;32:30–52. [PMC free article] [PubMed]
45. Favrat B., Menetrey A., Augsburger M., et al. Two cases of “cannabis acute psychosis” following the administration of oral cannabis. BMC Psychiatry. 2005;5:17. [PMC free article] [PubMed]
46. D’Souza DC., Perry E., MacDougall L., et al. The psychotomimetic effects of intravenous deIta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology.2004;29:1558–1572. [PubMed]
47. Ozaki S., Wada K. Amotivational syndrome in organic solvent abusers. Nippon Yakurigaku Zasshi.2001;117:42–48. [PubMed]
48. Fujiwara M. Characteristics of abnormal behavior induced by delta 9-tetrahydrocannabinol in rats. Nippon Yakurigaku Zasshi. 2001;117:35–41. [PubMed]
49. Tunving K. Psychiatric aspects of cannabis use in adolescents and young adults. Pediatrician.1987;14:83–91. [PubMed]
50. Laqueille X. Related, induced and associated psychiatric disorders to cannabis. Rev Prat. 2005;55:30–34. [PubMed]
51. Mendelson JH., Kuehnle JC., Greenberg I., Mello NK. Operant acquisition of marihuana in man. J Pharmacol Exp Ther. 1976;198:42–53. [PubMed]
52. Barnwell SS., Earleywine M., Wilcox R. Cannabis, motivation, and life satisfaction in an internet sample. Subst Abuse Treat Prev Policy. 2006;1:2. [PMC free article] [PubMed]
53. Wargo KA., Geveden BN., McConnell VJ. Cannabinoid-induced pancreatitis: a case series. JOP.2007;8:579–583. [PubMed]
54. Kirkham TC. Endocannabinoids in the regulation of appetite and body weight. Behav Pharmacol.2005;16:297–313. [PubMed]
55. Kirkham TC., Tucci SA. Endocannabinoids in appetite control and the treatment of obesity. CNS Neurol Disord Drug Targets. 2006;5:272–292. [PubMed]
56. Russo P., Strazzullo P., Cappuccio FP., et al. Genetic variations at the endocannabinoid type 1 receptor gene (CNR1) are associated with obesity phenotypes in men. J Clin Endocrinol Metab. 2007 [PubMed]
57. Gessa GL., Orru A., Lai P., et al. Lack of tolerance to the suppressing effect of rimonabant on chocolate intake in rats. Psychopharmacology (Berl). 2006;185:248–254. [PubMed]
58. Ward SJ., Dykstra LA. The role of CB1 receptors in sweet versus fat reinforcement: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940). Behav Pharmacol. 2005;16:381–388. [PubMed]
59. Simiand J., Keane M., Keane PE., Soubrie P. SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol. 1998;9:179–181. [PubMed]
60. Carai MA., Colombo G, Maccioni P., Gessa GL. Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data. CNS Drug Rev2006;12:91–99. [PubMed]
61. Pagotto U., Pasquali R. Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors. Lancet. 2005;365:1363–1364. [PubMed]
62. Despres JP., Golay A., Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353:2121–2134. [PubMed]
63. Pi-Sunyer FX., Aronne LJ., Heshmati HM., Devin J., Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006;295:761–775. [PubMed]
64. Van Gaal LF., Rissanen AM., Scheen AJ., Ziegler O., Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365:1389–1397. [PubMed]
65. Cleland JG., Ghosh J., Freemantle N., et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCDHeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail. 2004;6:501–508.[PubMed]
66. Scheen AJ., Van Gaal LG., Despres JP., Pi-Sunyer X., Golay A., Hanotin C. Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies. Rev Med Suisse.2006;2:1916–1923. [PubMed]
67. Shapiro H., Singer P. Rimonabant in obese patients with type 2 diabetes. Lancet. 2007;369:553–554; author reply 554-555. [PubMed]
68. Patel PN., Pathak R. Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity. Am J Health Syst Pharm. 2007;64:481–489. [PubMed]
69. Beal JE., Olson R., Lefkowitz L., et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage. 1997;14:7–14. [PubMed]
70. Beal JE., Olson R., Laubenstein L., et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage. 1995;10:89–97. [PubMed]
71. Gorter R., Seefried M., Volberding P. Dronabinol effects on weight in patients with HIV infection. AIDS. 1992;6:127. [PubMed]
72. Timpone JG., Wright DJ., Li N., et al. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRl 004 Study Group. Division of AIDS Treatment Research Initiative. AIDS Res Hum Retroviruses. 1997;13:305–315. [PubMed]
73. Nauck F., Klaschik E. Cannabinoids in the treatment of the cachexiaanorexia syndrome in palliative care patients. Schmerz. 2004;18:197–202. [PubMed]
74. Nelson K., Walsh D., Deeter P., Sheehan F. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care. 1994;10:14–18. [PubMed]
75. Martin BR., Wiley JL. Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain. J Support Oncol. 2004;2:305–314; discussion 314-306. [PubMed]
76. Abrahamov A., Abrahamov A., Mechoulam R. An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci. 1995;56:2097–2102. [PubMed]
77. Tramer MR., Carroll D., Campbell FA., Reynolds DJ., Moore RA., McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ. 2001;323:16–21. [PMC free article] [PubMed]
78. Liang YC., Huang CC., Hsu KS. Therapeutic potential of cannabinoids in trigeminal neuralgia. Curr Drug Targets CNS Neurol Disord. 2004;3:507–514. [PubMed]
79. Volfe Z., Dvilansky A., Nathan I. Cannabinoids block release of serotonin from platelets induced by plasma from migraine patients. Int J Clin Pharmacol Res. 1985;5:243–246. [PubMed]
80. Attal N., Brasseur L., Guirimand D., Clermond-Gnamien S., Atlami S., Bouhassira D. Are oral cannabinoids safe and effective in refractory neuropathic pain? Eur J Pain. 2004;8:173–177. [PubMed]
81. Buggy DJ., Toogood L., Marie S., Sharpe P., Lambert DG., Rowbotham DJ. Lack of analgesic efficacy of oral deIta-9-tetrahydrocannabinol in postoperative pain. Pain. 2003;106:169–172. [PubMed]
82. Holdcroft A., Smith M., Jacklin A., et al. Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia. 1997;52:483–486. [PubMed]
83. Berman JS., Symonds C., Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain.2004;112:299–306. [PubMed]
84. Svendsen KB., Jensen TS., Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ. 2004;329:253.[PMC free article] [PubMed]
85. Svendsen KB., Jensen TS., Bach FW. Effect of the synthetic cannabinoid dronabinol on central pain in patients with multiple sclerosis – secondary publication. Ugeskr Laeger. 2005;167:2772–2774. [PubMed]
86. Noyes R., Jr., Brunk SF., Avery DA., Canter AC. The analgesic properties of deIta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther. 1975;18:84–89. [PubMed]
87. Noyes R., Jr., Brunk SF., Baram DA., Canter A. Analgesic effect of deIta-9-tetrahydrocannabinol. J Clin Pharmacol. 1975;15:139–143. [PubMed]
88. Ware MA., Doyle CR., Woods R., Lynch ME., Clark AJ. Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain. 2003;102:211–216. [PubMed]
89. Woolridge E., Barton S., Samuel J., Osorio J., Dougherty A., Holdcroft A. Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manage. 2005;29:358–367. [PubMed]
90. Berlach DM., Shir Y., Ware MA. Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. Pain Med. 2006;7:25–29. [PubMed]
91. Wissel J., Haydn T., MuIIer J., et al. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. J Neurol.2006;253:1337–1341. [PubMed]
92. Karst M., Salim K., Burstein S., Conrad I., Hoy L., Schneider U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA. 2003;290:1757–1762.[PubMed]
93. Vann RE., Cook CD., Martin BR., Jenny L., Wiley JL. Cannabimimetic properties of ajulemic acid. J Pharmacol Exp Ther. 2007;320:678–686. [PubMed]
94. Russo E., Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses. 2006;66:234–246. [PubMed]
95. Iskedjian M., Bereza B., Gordon A., Piwko C., Einarson TR. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin. 2007;23:17–24.[PubMed]
96. Notcutt W., Price M., Miller R., et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 ‘N of 1’ studies. Anaesthesia. 2004;59:440–452. [PubMed]
97. Rog DJ., Nurmikko TJ., Friede T., Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65:812–819. [PubMed]
98. Barnes MP. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Exp Opin Pharmacother. 2006;7:607–615. [PubMed]
99. Perez J. Combined cannabinoid therapy via an oromucosal spray. Drugs Today (Bare). 2006;42:495–503. [PubMed]
100. Ware M., Beaulieu P. Cannabinoids for the treatment of pain: An update on recent clinical trials. Pain Res Manag. 2005;10 (suppl A):27A–30A. [PubMed]
101. Achiron A., Miron S., Lavie V., Margalit R., Biegon A. Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis. J Neuroimmunol. 2000;102:26–31. [PubMed]
102. Lyman WD., Sonett JR., Brosnan CF., Elkin R., Bornstein MB. Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J Neuroimmunol. 1989;23:73–81. [PubMed]
103. Sanchez AJ., Gonzalez-Perez P., Galve-Roperh I., Garcia-Merino A. R-(+)-[2,3-Dihydro-5-methyI-3-(4-morphoIinyImethyI)-pyrroIo-[1,2,3-de]-1,4-benzoxazin-6-yI]-1-naphta!enyImethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: partial involvement of the CB(2) receptor. Biochem Pharmacol. 2006;72:1697–1706. [PubMed]
104. Docagne F., Muneton V., Clemente D., et al. Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation. Mol Cell Neurosci.2007;34:551–561. [PubMed]
105. Benito C., Romero JP., Tolon RM., et al. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci.2007;27:2396–2402. [PubMed]
106. Cabranes A., Pryce G., Baker D., Fernandez-Ruiz J. Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice. Brain Res. 2006;1107:199–205. [PubMed]
107. Petro DJ. Marihuana as a therapeutic agent for muscle spasm or spasticity. Psychosomatics.1980;21:81–85. [PubMed]
108. Pryce G., Baker D. Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br J Pharmacol. 2007;150:519–525. [PMC free article] [PubMed]
109. UngerIeider JT., Andyrsiak T., Fairbanks L., Ellison GW., Myers LW. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse. 1987;7:39–50. [PubMed]
110. Martyn CN., lllis LS., Thom J. Nabilone in the treatment of multiple sclerosis. Lancet. 1995;345:579.[PubMed]
111. Meinck HM., Schonle PW., Conrad B. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol. 1989;236:120–122. [PubMed]
112. Petro DJ., Ellenberger C., Jr. Treatment of human spasticity with delta-9-tetrahydrocannabinol. J Clin Pharmacol. 1981;21:413S–416S. [PubMed]
113. Brenneisen R., Egli A., Elsohly MA., Henn V., Spiess Y. The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther.1996;34:446–452. [PubMed]
114. Koch M., Mostert J., Heersema D., De Keyser J. Tremor in multiple sclerosis. J Neurol.2007;254:133–145. [PMC free article] [PubMed]
115. Killestein J., Hoogervorst EL., Reif M., et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology. 2002;58:1404–1407. [PubMed]
116. Greenberg HS., Werness SA., Pugh JE., Andrus RO., Anderson DJ., Domino EF. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther. 1994;55:324–328. [PubMed]
117. Clifford DB. Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol. 1983;13:669–671.[PubMed]
118. Fox P., Bain PG., Glickman S., Carroll C., Zajicek J. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology. 2004;62:1105–1109. [PubMed]
119. Schon F., Hart PE., Hodgson TL., et al. Suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis. Neurology. 1999;53:2209–2210. [PubMed]
120. Freeman RM., Adekanmi O., Waterfield MR., Waterfield AE., Wright D., Zajicek J. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMSLUTS). Int Urogynecol J Pelvic Floor Dysfunct. 2006;17:636–641. [PubMed]
121. Smith PF. GW-1000. GW Pharmaceuticals. Curr Opin Investig Drugs. 2004;5:748–754. [PubMed]
122. Vaney C., Heinzel-Gutenbrunner M., Jobin P., et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler. 2004;10:417–424. [PubMed]
123. Wade DT., Makela P., Robson P., House H., Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10:434–441. [PubMed]
124. Wade DT., Makela PM., House H., Bateman C., Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler. 2006;12:639–645. [PubMed]
125. Zajicek J., Fox P., Sanders H., et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet.2003;362:1517–1526. [PubMed]
126. Zajicek JP., Sanders HP., Wright DE., et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry. 2005;76:1664–1669.[PMC free article] [PubMed]
127. BifuIco M., Laezza C., Malfitano AM. From anecdotal evidence of cannabinoids in multiple sclerosis to emerging new therapeutical approaches. Mult Scler. 2007;13:133–134. [PubMed]
128. BowIing A. Cannabinoids in MS – are we any closer to knowing how best to use them? Mult Scler.2006;12:523–525. [PubMed]
129. Maccarrone M., Battista N., Centonze D. The endocannabinoid pathway in Huntington’s disease: a comparison with other neurodegenerative diseases. Prog Neurobiol. 2007;81:349–379. [PubMed]
130. Mestre L., Correa F., Docagne F., et al. Cannabinoid system and neuroinflammation: therapeutic perspectives in multiple sclerosis. Rev Neurol. 2006;43:541–548. [PubMed]
131. Lastres-Becker I., Molina-Holgado F., Ramos JA., Mechoulam R., Fernandez-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease. Neurobiol Dis. 2005;19:96–107. [PubMed]
132. Sommer C., Schomacher M., Berger C., et al. Neuroprotective cannabinoid receptor antagonist SR141716A prevents downregulation of excitotoxic NMDA receptors in the ischemic penumbra. Acta Neuropathol (Berl). 2006;112:277–286. [PubMed]
133. KnoIler N., Levi L., Shoshan I., et al. Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. Crit Care Med. 2002;30:548–554.[PubMed]
134. Maas AI., Murray G., Henney H., 3rd., et al. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol. 2006;5:38–45. [PubMed]
135. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol.2005;5:400–411. [PubMed]
136. Walter L., Stella N. Cannabinoids and neuroinflammation. Br J Pharmacol. 2004;141:775–785.[PMC free article] [PubMed]
137. Marchalant Y., Rosi S., Wenk GL. Anti-inflammatory property of the cannabinoid agonist WIN-55212-2 in a rodent model of chronic brain inflammation. Neuroscience. 2007;144:1516–1522.[PMC free article] [PubMed]
138. Maresz K., Pryce G., Ponomarev ED., et al. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB(1) on neurons and CB(2) on autoreactive T cells. Nat Med. 2007;13:492–497.[PubMed]
139. Steffens S., Veillard NR., Arnaud C., et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature. 2005;434:782–786. [PubMed]
140. Darmani NA., Izzo AA., Degenhardt B., et al. Involvement of the cannabimimetic compound, N-palmitoyl-ethanoIamine, in inflammatory and neuropathic conditions: Review of the available pre-clinical data, and first human studies. Neuropharmacology. 2005;48:1154–1163. [PubMed]
141. Rajesh M., Mukhopadhyay P., Batkai S., et al. Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Am J Physiol Heart Ore Physiol.2007;293:H909–H918. [PMC free article] [PubMed]
142. Croci T., Zarini E. Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats. Br J Pharmacol. 2007;150:559–566.[PMC free article] [PubMed]
143. Brotchie JM. CB1 cannabinoid receptor signalling in Parkinson’s disease. Curr Opin Pharmacol.2003;3:54–61. [PubMed]
144. Maneuf YP., Crossman AR., Brotchie JM. The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson’s disease. Exp Neurol. 1997;148:265–270. [PubMed]
145. Ferrer B., Asbrock N., Kathuria S., Piomelli D., Giuffrida A. Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. Eur J Neurosci.2003;18:1607–1614. [PubMed]
146. Gonzalez S., Scorticati C., Garcia-Arencibia M., de Miguel R., Ramos JA., Fernandez-Ruiz J. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson’s disease. Brain Res. 2006;1073-1074:209–219. [PubMed]
147. Lastres-Becker I., Cebeira M., de Ceballos ML., et al. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson’s syndrome and of MPTP-treated marmosets. Eur J Neurosci. 2001;14:1827–1832. [PubMed]
148. Pisani A., Fezza F., Galati S., et al. High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson’s disease patients. Ann Neurol. 2005;57:777–779. [PubMed]
149. Kreitzer AC., Malenka RC. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson’s disease models. Nature. 2007;445:643–647. [PubMed]
150. Sieradzan KA., Fox SH., Hill M., Dick JP., Crossman AR., Brotchie JM. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: a pilot study. Neurology. 2001;57:2108–2111.[PubMed]
151. Jabusch HC., Schneider U., AltenmuIIer E. DeIta9-tetrahydrocannabinol improves motor control in a patient with musician’s dystonia. Mov Disord. 2004;19:990–991. [PubMed]
152. Carroll CB., Bain PG., Teare L., et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology. 2004;63:1245–1250. [PubMed]
153. Fox SH., Kellett M., Moore AP., Crossman AR., Brotchie JM. Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov Disord. 2002;17:145–149. [PubMed]
154. Mesnage V., Houeto JL., Bonnet AM., et al. Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease. Clin Neuropharmacol. 2004;27:108–110. [PubMed]
155. Venderova K., Ruzicka E., Vorisek V., Visnovsky P. Survey on cannabis use in Parkinson’s disease: subjective improvement of motor symptoms. Mov Disord. 2004;19:1102–1106. [PubMed]
156. AIsasua del Valle A. Implication of cannabinoids in neurological diseases. Cell Mol Neurobiol.2006;26:579–591. [PubMed]
157. Lastres-Becker I., Fernandez-Ruiz J. An overview of Parkinson’s disease and the cannabinoid system and possible benefits of cannabinoid-based treatments. Curr Med Chem. 2006;13:3705–3718. [PubMed]
158. Sevcik J., Masek K. Potential role of cannabinoids in Parkinson’s disease. Drugs Aging. 2000;16:391–395. [PubMed]
159. Glass M., Dragunow M., Faull RL. The pattern of neurodegeneration in Huntington’s disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington’s disease. Neuroscience. 2000;97:505–519. [PubMed]
160. Richfield EK., Herkenham M. Selective vulnerability in Huntington’s disease: preferential loss of cannabinoid receptors in lateral globus pallidus. Ann Neurol. 1994;36:577–584. [PubMed]
161. Glass M., Faull RL., Dragunow M. Loss of cannabinoid receptors in the substantia nigra in Huntington’s disease. Neuroscience. 1993;56:523–527. [PubMed]
162. de Lago E., Urbani P., Ramos JA., Di Marzo V., Fernandez-Ruiz J. Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington’s disease. Brain Res. 2005;1050:210–216. [PubMed]
163. Lastres-Becker I., de Miguel R., De Petrocellis L., Makriyannis A., Di Marzo V., Fernandez-Ruiz J. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington’s disease. J Neurochem. 2003;84:1097–1109. [PubMed]
164. Pintor A., Tebano MT., Martire A., et al. The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum. Neuropharmacology. 2006;51:1004–1012.[PubMed]
165. Consroe P., Laguna J., AHender J., et al. Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol Biochem Behav. 1991;40:701–708. [PubMed]
166. MulIer-Vahl KR. Cannabinoids reduce symptoms of Tourette’s syndrome. Expert Opin Pharmacother.2003;4:1717–1725. [PubMed]
167. Muller-Vahl KR., Prevedel H., Theloe K., Kolbe H., Emrich HM., Schneider U. Treatment of Tourette syndrome with deIta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance. Neuropsychopharmacology. 2003;28:384–388. [PubMed]
168. MuIIer-VahI KR., Schneider U., Koblenz A., et al. Treatment of Tourette’s syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry. 2002;35:57–61.[PubMed]
169. MuIIer-Vahl KR., Schneider U., Prevedel H., et al. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry. 2003;64:459–465.[PubMed]
170. Gadzicki D., MuIIer-Vahl KR., Heller D., et al. Tourette syndrome is not caused by mutations in the central cannabinoid receptor (CNR1) gene. Am J Med Genet B Neuropsychiatr Genet. 2004;127:97–103.[PubMed]
171. Carter GT., Rosen BS. Marijuana in the management of amyotrophic lateral sclerosis. Am J Hosp Palliat Care. 2001;18:264–270. [PubMed]
172. Bilsland LG., Dick JR., Pryce G., et al. Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. Faseb J. 2006;20:1003–1005. [PubMed]
173. Raman C., McAllister SD., Rizvi G., Patel SG., Moore DH., Abood ME. Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5:33–39. [PubMed]
174. Weydt P., Hong S., Witting A., MoIIer T., Stella N., Kliot M. Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6:182–184. [PubMed]
175. Kim K., Moore DH., Makriyannis A., Abood ME. AM 1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol. 2006;542:100–105. [PubMed]
176. Shoemaker JL., Seely KA., Reed RL., Crow JP., Prather PL. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem. 2007;101:87–98. [PMC free article] [PubMed]
177. Amtmann D., Weydt P., Johnson KL., Jensen MP., Carter GT. Survey of cannabis use in patients with amyotrophic lateral sclerosis. Am J Hosp Palliat Care. 2004;21:95–104. [PubMed]
178. Eubanks LM., Rogers CJ., Beuscher AE. 4th., et al. A molecular link between the active component of marijuana and Alzheimer’s disease pathology. Mol Pharm. 2006;3:773–777. [PMC free article][PubMed]
179. VoIicer L., Stelly M., Morris J., McLaughlin J., Volicer BJ. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. Int J Geriatr Psychiatry. 1997;12:913–919.[PubMed]
180. WaIther S., Mahlberg R., Eichmann U., Kunz D. DeIta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology (Berl). 2006;185:524–528. [PubMed]
181. Carlini EA., Mechoulam R., Lander N. Anticonvulsant activity of four oxygenated cannabidiol derivatives. Res Commun Chem Pathol Pharmacol. 1975;12:1–15. [PubMed]
182. Consroe P., Martin A., Singh V. Antiepileptic potential of cannabidiol analogs. J Clin Pharmacol.1981;21:428S–436S. [PubMed]
183. Martin AR., Consroe P., Kane W., et al. Structure-anticonvulsant activity relationships of cannabidiol analogs. NIDA Res Monogr. 1987;79:48–58. [PubMed]
184. Ames FR., Cridland S. Anticonvulsant effect of cannabidiol. S Afr Med J. 1986;69:14. [PubMed]
185. Consroe P., Wolkin A. Cannabidiol-antiepileptic drug comparisons and interactions in experimentally induced seizures in rats. J Pharmacol Exp Ther. 1977;201:26–32. [PubMed]
186. Consroe PF., Wolkin AL. Anticonvulsant interaction of cannabidiol and ethosuximide in rats. J Pharm Pharmacol. 1977;29:500–501. [PubMed]
187. Cortesi M., Fusar-Poli P. Potential therapeutical effects of cannabidiol in children with pharmacoresistant epilepsy. Med Hypotheses. 2007;68:920–921. [PubMed]
188. Deshpande LS., Sombati S., Blair RE., Carter DS., Martin BR., DeLorenzo RJ. Cannabinoid CB1 receptor antagonists cause status epilepticus-Iike activity in the hippocampal neuronal culture model of acquired epilepsy. Neurosci Lett. 2007;411:11–16. [PMC free article] [PubMed]
189. Luszczki JJ., Czuczwar P., Cioczek-Czuczwar A., Czuczwar SJ. Arachidonyl-2′-chIoroethyIamide, a highly selective cannabinoid CB1 receptor agonist, enhances the anticonvulsant action of valproate in the mouse maximal electroshock-induced seizure model. Eur J Pharmacol. 2006;547:65–74. [PubMed]
190. Gordon E., Devinsky O. Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia. 2001;42:1266–1272. [PubMed]
191. Keeler MH., Reifler CB. Grand mal convulsions subsequent to marijuana use. Case report. Dis Nerv Syst. 1967;28:474–475. [PubMed]
192. Cunha JM., Carlini EA., Pereira AE., et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology. 1980;21:175–185. [PubMed]
193. Ashton CH., Moore PB., Gallagher P., Young AH. Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. J Psychopharmacol. 2005;19:293–300. [PubMed]
194. Grinspoon L., Bakalar JB. The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research. J Psychoactive Drugs. 1998;30:171–177. [PubMed]
195. Emrich HM., Leweke FM., Schneider U. Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacol Biochem Behav. 1997;56:803–807. [PubMed]
196. Leweke FM., Giuffrida A., Koethe D., et al. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: Impact of cannabis use. Schizophr Res. 2007;94:29–36. [PubMed]
197. Kenchadze VG., Chkoniia ED. Clinical features of cannabis psychosis in schizophrenia patients. Georgian Med News. 2006:55–58. [PubMed]
198. McGuire PK., Jones P., Harvey I., et al. Cannabis and acute psychosis. Schizophr Res. 1994;13:161–167. [PubMed]
199. Jockers-Scherubl MC. Schizophrenia and cannabis consumption: epidemiology and clinical symptoms. Prax Kinderpsychol Kinderpsychiatr. 2006;55:533–543. [PubMed]
200. BoydeII J., Dean K., Dutta R., Giouroukou E., Fearon P., Murray R. A comparison of symptoms and family history in schizophrenia with and without prior cannabis use: Implications for the concept of cannabis psychosis. Schizophr Res. 2007;93:203–210. [PubMed]
201. Dubertret C., Bidard I., Ades J., Gorwood P. Lifetime positive symptoms in patients with schizophrenia and cannabis abuse are partially explained by co-morbid addiction. Schizophr Res.2006;86:284–290. [PubMed]
202. Meltzer HY., Arvanitis L., Bauer D., Rein W. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry. 2004;161:975–984.[PubMed]
203. Zuardi AW., Morais SL., Guimaraes FS., Mechoulam R. Antipsychotic effect of cannabidiol. J Clin Psychiatry. 1995;56:485–486. [PubMed]
204. Zuardi AW., Crippa JA., Hallak JE., Moreira FA., Guimaraes FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res. 2006;39:421–429. [PubMed]
205. Zuardi AW., Hallak JE., Dursun SM., et al. Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol. 2006;20:683–686. [PubMed]
206. Chhatwal JP., Davis M., Maguschak KA., Ressler KJ. Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology. 2005;30:516–524. [PubMed]
207. Varvel SA., Wise LE., Niyuhire F., Cravatt BF., Lichtman AH. Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task. Neuropsychopharmacology.2007;32:1032–1041. [PubMed]
208. Fride E., Suris R., Weidenfeld J., Mechoulam R. Differential response to acute and repeated stress in cannabinoid CB1 receptor knockout newborn and adult mice. Behav Pharmacol. 2005;16:431–440.[PubMed]
209. Calhoun PS., Sampson WS., Bosworth HB., et al. Drug use and validity of substance use self-reports in veterans seeking help for posttraumatic stress disorder. J Consult Clin Psychol. 2000;68:923–927.[PubMed]
210. Barrero FJ., Ampuero I., Morales B., et al. Depression in Parkinson’s disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1). Pharmacogenomics J. 2005;5:135–141.[PubMed]
211. Guimaraes FS., Chiaretti TM., Graeff FG., Zuardi AW. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl). 1990;100:558–559. [PubMed]
212. Guimaraes FS., de Aguiar JC., Mechoulam R., Breuer A. Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze. Gen Pharmacol. 1994;25:161–164. [PubMed]
213. Glass RM., Uhlenhuth EH., Hartel FW., Schuster CR., Fischman MW. A single dose study of nabilone, a synthetic cannabinoid. Psychopharmacology (Berl). 1980;71:137–142. [PubMed]
214. Fabre LF., McLendon D. The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety. J Clin Pharmacol. 1981;21:377S–382S. [PubMed]
215. Barratt ES., Beaver W., White R. The effects of marijuana on human sleep patterns. Biol Psychiatry.1974;8:47–54. [PubMed]
216. Freemon FR. Effects of marihuana on sleeping states. JAMA. 1972;220:1364–1365. [PubMed]
217. Pivik RT., Zarcone V., Dement WC., Hollister LE. DeIta-9-tetrahydrocannabinol and synhexl: effects on human sleep patterns. Clin Pharmacol Ther. 1972;13:426–435. [PubMed]
218. Feinberg I., Jones R., Walker J., Cavness C., Floyd T. Effects of marijuana extract and tetrahydrocannabinol on electroencephalographic sleep patterns. Clin Pharmacol Ther. 1976;19:782–794.[PubMed]
219. Feinberg I., Jones R., Walker JM., Cavness C., March J. Effects of high dosage deIta-9-tetrahydrocannabinol on sleep patterns in man. Clin Pharmacol Ther. 1975;17:458–466. [PubMed]
220. Nicholson AN., Turner C., Stone BM., Robson PJ. Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacol.2004;24:305–313. [PubMed]
221. Tashkin DP., Shapiro BJ., Lee YE., Harper CE. Effects of smoked marijuana in experimentally induced asthma. Am Rev Respir Dis. 1975;112:377–386. [PubMed]
222. Tashkin DP., Calvarese BM., Simmons MS., Shapiro BJ. Respiratory status of seventy-four habitual marijuana smokers. Chest. 1980;78:699–706. [PubMed]
223. Abboud RT., Sanders HD. Effect of oral administration of delta-tetrahydrocannabinol on airway mechanics in normal and asthmatic subjects. Chest. 1976;70:480–485. [PubMed]
224. Tashkin DP., Shapiro BJ., Frank IM. Acute effects of smoked marijuana and oral delta-9-tetrahydrocannabinol on specific airway conductance in asthmatic subjects. Am Rev Respir Dis.1974;109:420–428. [PubMed]
225. Tashkin DP., Shapiro BJ., Frank IM. Acute pulmonary physiologic effects of smoked marijuana and oral 9 -tetrahydrocannabinol in healthy young men. N Engl J Med. 1973;289:336–341. [PubMed]
226. Gong H., Jr., Tashkin DP., Simmons MS., Calvarese B., Shapiro BJ. Acute and subacute bronchial effects of oral cannabinoids. Clin Pharmacol Ther. 1984;35:26–32. [PubMed]
227. Hartley JP., Nogrady SG., Seaton A. Bronchodilator effect of deltaltetrahydrocannabinol. Br J Clin Pharmacol. 1978;5:523–525. [PMC free article] [PubMed]
228. Williams SJ., Hartley JP., Graham JD. Bronchodilator effect of deltaltetrahydrocannabinol administered by aerosol of asthmatic patients. Thorax. 1976;31:720–723. [PMC free article] [PubMed]
229. Benowitz NL., Rosenberg J., Rogers W., Bachman J., Jones RT. Cardiovascular effects of intravenous delta-9-tetrahydrocannabinol: autonomic nervous mechanisms. Clin Pharmacol Ther. 1979;25:440–446.[PubMed]
230. Kanakis C., Jr., Pouget JM., Rosen KM. The effects of deIta-9-tetrahydrocannabinol (cannabis) on cardiac performance with and without beta blockade. Circulation. 1976;53:703–707. [PubMed]
231. Tashkin DP., Levisman JA., Abbasi AS., Shapiro BJ., Ellis NM. Short-term effects of smoked marihuana on left ventricular function in man. Chest. 1977;72:20–26. [PubMed]
232. Benowitz NL., Jones RT. Cardiovascular effects of prolonged delta-9tetrahydrocannabinol ingestion. Clin Pharmacol Ther. 1975;18:287–297. [PubMed]
233. Benowitz NL., Jones RT. Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man. J Clin Pharmacol. 1981;21:214S–223S. [PubMed]
234. GoreIick DA., Heishman SJ., Preston KL., Nelson RA., Moolchan ET., Huestis MA. The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers. Am Heart J. 2006;151:754 e751–754 e755. [PubMed]
235. EisohIy MA., Harland E., Murphy JC., Wirth P., Waller CW. Cannabinoids in glaucoma: a primary screening procedure. J Clin Pharmacol. 1981;21:472S–478S. [PubMed]
236. ElSohly MA., Harland EC., Benigni DA., Waller CW. Cannabinoids in glaucoma II: the effect of different cannabinoids on intraocular pressure of the rabbit. Curr Eye Res. 1984;3:841–850. [PubMed]
237. BuchwaId A., Derendorf H., Ji F., Nagaraja NY., Wu WM., Bodor N. Soft cannabinoid analogues as potential anti-glaucoma agents. Pharmazie. 2002;57:108–114. [PubMed]
238. Laine K., Jarvinen K., Mechoulam R., Breuer A., Jarvinen T. Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid. Invest Ophthalmol Vis Sci. 2002;43:3216–3222. [PubMed]
239. Laine K., Jarvinen K., Pate DW., Urtti A., Jarvinen T. Effect of the enzyme inhibitor, phenylmethylsulfonyl fluoride, on the IOP profiles of topical anandamides. Invest Ophthalmol Vis Sci.2002;43:393–397. [PubMed]
240. Pate DW., Jarvinen K., Urtti A., Jarho P., Jarvinen T. Ophthalmic arachidonylethanolamide decreases intraocular pressure in normotensive rabbits. Curr Eye Res. 1995;14:791–797. [PubMed]
241. Porcella A., Casellas P., Gessa GL., Pani L. Cannabinoid receptor CB1 mRNA is highly expressed in the rat ciliary body: implications for the antiglaucoma properties of marihuana. Brain Res Mol Brain Res.1998;58:240–245. [PubMed]
242. Colasanti BK., Brown RE., Craig CR. Ocular hypotension, ocular toxicity, and neurotoxicity in response to marihuana extract and cannabidiol. Gen Pharmacol. 1984;15:479–484. [PubMed]
243. Colasanti BK., Craig CR., Allara RD. Intraocular pressure, ocular toxicity and neurotoxicity after administration of cannabinol or cannabigerol. Exp Eye Res. 1984;39:251–259. [PubMed]
244. CoIasanti BK., Powell SR., Craig CR. Intraocular pressure, ocular toxicity and neurotoxicity after administration of delta 9-tetrahydrocannabinol or cannabichromene. Exp Eye Res. 1984;38:63–71.[PubMed]
245. HepIer RS., Frank IR. Marihuana smoking and intraocular pressure. Jama. 1971;217:1392. [PubMed]
246. Merritt JC., Olsen JL., Armstrong JR., McKinnon SM. Topical delta 9-tetrahydrocannabinol in hypertensive glaucomas. J Pharm Pharmacol. 1981;33:40–41. [PubMed]
247. Merritt JC., Perry DD., Russell DN., Jones BF. Topical delta 9-tetrahydrocannabinol and aqueous dynamics in glaucoma. J Clin Pharmacol. 1981;21:467S–471S. [PubMed]
248. Merritt JC., Crawford WJ., Alexander PC., Anduze AL., Gelbart SS. Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology. 1980;87:222–228. [PubMed]
249. PurneII WD., Gregg JM. DeIta(9)-tetrahydrocannabinoI, euphoria and intraocular pressure in man. Ann Ophthalmol. 1975;7:921–923. [PubMed]
250. Crawford WJ., Merritt JC. Effects of tetrahydrocannabinol on arterial and intraocular hypertension. IntJ Clin Pharmacol Biopharm. 1979;17:191–196. [PubMed]
251. Tomida I., Azuara-BIanco A., House H., Flint M., Pertwee RG., Robson PJ. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J Glaucoma. 2006;15:349–353.[PubMed]
252. Hall W., Christie M., Currow D. Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncol. 2005;6:35–42. [PubMed]
253. Kogan NM. Cannabinoids and cancer. Mini Rev Med Chem. 2005;5:941–952. [PubMed]
254. Bifulco M., Laezza C., Gazzerro P., Pentimalli F. Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion (review). Oncol Rep. 2007;17:813–816. [PubMed]
255. Aguado T., Carracedo A., Julien B., et al. Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis. J Biol Chem. 2007;282:6854–6862. [PubMed]
256. Massi P., Vaccani A., Bianchessi S., Costa B., Macchi P., Parolaro D. The nonpsychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell Mol Life Sci.2006;63:2057–2066. [PubMed]
257. BIazquez C., Carracedo A., Barrado L., et al. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J. 2006;20:2633–2635. [PubMed]
258. Caffarel MM., Sarrio D., Palacios J., Guzman M., Sanchez C. Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res. 2006;66:6615–6621. [PubMed]
259. Carracedo A., Gironella M., Lorente M., et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res. 2006;66:6748–6755. [PubMed]
260. Jia W., Hegde VL., Singh NP., et al. Delta9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria. Mol Cancer Res. 2006;4:549–562.[PubMed]
261. McKallip RJ., Jia W., Schlomer J., Warren JW., Nagarkatti PS., Nagarkatti M. Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression. Mol Pharmacol. 2006;70:897–908. [PubMed]
262. Sarfaraz S., Afaq F., Adhami VM., Malik A., Mukhtar H. Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. J Biol Chem. 2006;281:39480–39491. [PubMed]
263. Sarnataro D., Pisanti S., Santoro A., et al. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism. Mol Pharmacol. 2006;70:1298–1306. [PubMed]
264. Guzman M., Duarte MJ., Blazquez C., et al. A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95:197–203. [PMC free article][PubMed]
265. McClung CA. The molecular mechanisms of morphine addiction. Rev Neurosci. 2006;17:393–402.[PubMed]
266. Harper SJ., Jones NS. Cocaine: what role does it have in current ENT practice? A review of the current literature. J Laryngol Otol. 2006;120:808–811. [PubMed]
267. O’Brien C. P. Benzodiazepine use, abuse, and dependence. J Clin Psychiatry. 2005;66 SuppI 2:28–33.[PubMed]
268. Lader M. Anxiolytic drugs: dependence, addiction and abuse. Eur Neuropsychopharmacol.1994;4:85–91. [PubMed]
269. Luetje CM., Wooten J. Clinical manifestations of transdermal scopolamine addiction. Ear Nose Throat J. 1996;75:210–214. [PubMed]
270. Jansen KL. A review of the nonmedical use of ketamine: use, users and consequences. J Psychoactive Drugs. 2000;32:419–433. [PubMed]
271. Jansen KL., Darracot-Cankovic R. The nonmedical use of ketamine, part two: A review of problem use and dependence. J Psychoactive Drugs. 2001;33:151–158. [PubMed]
272. Linazaroso G., van Blercom N., Lasa A. [Hypothesis: Parkinson’s disease, reward deficiency syndrome and addictive effects of levodopa]. Neurologia. 2004;19:117–127. [PubMed]
273. Greenhill LL. The science of stimulant abuse. Pediatr Ann. 2006;35:552–556. [PubMed]
274. Karsak M., Cohen-Solal M., Freudenberg J., et al. Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum Mol Genet. 2005;14:3389–3396. [PubMed]
275. Ofek O., Karsak M., Leclerc N., et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A. 2006;103:696–701. [PMC free article] [PubMed]
276. Begg M., Pacher P., Batkai S., et al. Evidence for novel cannabinoid receptors. Pharmacol Ther.2005;106:133–145. [PubMed]
277. Fride E., Foox A., Rosenberg E., et al. Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a “CB3” receptor. Eur J Pharmacol. 2003;461:27–34. [PubMed]
278. Baker D., Pryce G., Davies WL., Hiley CR. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci. 2006;27:1–4. [PubMed]

EQUAL MEDICINE ORGANIZATION - Marijuana ALS Amyotrophic Lateral Sclerosis Treatment cures medical marijuana thc cannabis cbd